Abaci H E, Guo Zongyou, Doucet Yanne, Jacków Joanna, Christiano Angela
1 Department of Dermatology, Columbia University Medical Center, New York, NY 10032, USA.
2 Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA.
Exp Biol Med (Maywood). 2017 Nov;242(17):1657-1668. doi: 10.1177/1535370217712690. Epub 2017 Jun 7.
Many diseases, as well as side effects of drugs, manifest themselves through skin symptoms. Skin is a complex tissue that hosts various specialized cell types and performs many roles including physical barrier, immune and sensory functions. Therefore, modeling skin in vitro presents technical challenges for tissue engineering. Since the first attempts at engineering human epidermis in 1970s, there has been a growing interest in generating full-thickness skin constructs mimicking physiological functions by incorporating various skin components, such as vasculature and melanocytes for pigmentation. Development of biomimetic in vitro human skin models with these physiological functions provides a new tool for drug discovery, disease modeling, regenerative medicine and basic research for skin biology. This goal, however, has long been delayed by the limited availability of different cell types, the challenges in establishing co-culture conditions, and the ability to recapitulate the 3D anatomy of the skin. Recent breakthroughs in induced pluripotent stem cell (iPSC) technology and microfabrication techniques such as 3D-printing have allowed for building more reliable and complex in vitro skin models for pharmaceutical screening. In this review, we focus on the current developments and prevailing challenges in generating skin constructs with vasculature, skin appendages such as hair follicles, pigmentation, immune response, innervation, and hypodermis. Furthermore, we discuss the promising advances that iPSC technology offers in order to generate in vitro models of genetic skin diseases, such as epidermolysis bullosa and psoriasis. We also discuss how future integration of the next generation human skin constructs onto microfluidic platforms along with other tissues could revolutionize the early stages of drug development by creating reliable evaluation of patient-specific effects of pharmaceutical agents. Impact statement Skin is a complex tissue that hosts various specialized cell types and performs many roles including barrier, immune, and sensory functions. For human-relevant drug testing, there has been a growing interest in building more physiological skin constructs by incorporating different skin components, such as vasculature, appendages, pigment, innervation, and adipose tissue. This paper provides an overview of the strategies to build complex human skin constructs that can faithfully recapitulate human skin and thus can be used in drug development targeting skin diseases. In particular, we discuss recent developments and remaining challenges in incorporating various skin components, availability of iPSC-derived skin cell types and in vitro skin disease models. In addition, we provide insights on the future integration of these complex skin models with other organs on microfluidic platforms as well as potential readout technologies for high-throughput drug screening.
许多疾病以及药物的副作用都会通过皮肤症状表现出来。皮肤是一种复杂的组织,包含各种特殊的细胞类型,并发挥着许多作用,包括物理屏障、免疫和感觉功能。因此,体外构建皮肤模型对组织工程来说存在技术挑战。自20世纪70年代首次尝试构建人表皮以来,人们越来越有兴趣通过整合各种皮肤成分(如用于色素沉着的血管和黑素细胞)来生成模拟生理功能的全层皮肤构建体。开发具有这些生理功能的仿生体外人皮肤模型为药物发现、疾病建模、再生医学以及皮肤生物学的基础研究提供了一种新工具。然而,由于不同细胞类型的可用性有限、建立共培养条件的挑战以及再现皮肤三维解剖结构的能力,这一目标长期以来一直被推迟。诱导多能干细胞(iPSC)技术和微制造技术(如3D打印)的最新突破使得构建更可靠、更复杂的体外皮肤模型用于药物筛选成为可能。在这篇综述中,我们重点关注在生成具有血管、毛囊等皮肤附属器、色素沉着、免疫反应、神经支配和皮下组织的皮肤构建体方面的当前进展和主要挑战。此外,我们讨论了iPSC技术在生成遗传性皮肤病(如大疱性表皮松解症和银屑病)的体外模型方面所提供的有前景的进展。我们还讨论了未来将下一代人皮肤构建体与微流控平台上的其他组织整合在一起,如何通过对药物制剂的患者特异性效应进行可靠评估,从而彻底改变药物开发的早期阶段。影响声明皮肤是一种复杂组织,包含各种特殊细胞类型,并发挥着包括屏障、免疫和感觉功能等多种作用。对于与人类相关的药物测试,人们越来越有兴趣通过整合不同的皮肤成分(如血管、附属器、色素、神经支配和脂肪组织)来构建更具生理功能的皮肤构建体。本文概述了构建能够忠实地再现人类皮肤从而可用于针对皮肤病的药物开发的复杂人皮肤构建体的策略。特别是,我们讨论了在整合各种皮肤成分、iPSC衍生的皮肤细胞类型的可用性以及体外皮肤疾病模型方面的最新进展和 remaining challenges(原文此处有误,推测可能是remaining challenges,可译为“剩余挑战”)。此外,我们还对这些复杂皮肤模型未来与微流控平台上的其他器官的整合以及高通量药物筛选的潜在读出技术提供了见解。